<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03159455</url>
  </required_header>
  <id_info>
    <org_study_id>1386-0007</org_study_id>
    <nct_id>NCT03159455</nct_id>
  </id_info>
  <brief_title>This Study Tests BI 1467335 in Healthy Japanese and Caucasian Men. The Study Tests How Different Doses of BI 1467335 Are Taken up in the Body and How Well They Are Tolerated</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1467335 in Healthy Japanese Male Volunteers With Multiple Oral Doses at the Highest Dose in Caucasian for Comparison (Randomised, Double-blind, Placebo-controlled Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the current study is to investigate the safety and tolerability of&#xD;
      BI 1467335 in healthy Japanese male subjects following oral administration of multiple rising&#xD;
      doses The Caucasian group will receive higher dose only.&#xD;
&#xD;
      A secondary objective is the exploration of the pharmacokinetics and pharmacodynamics of BI&#xD;
      1467335 in healthy Japanese and Caucasian male subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 7, 2017</start_date>
  <completion_date type="Actual">December 16, 2017</completion_date>
  <primary_completion_date type="Actual">December 16, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Drug-related Adverse Events</measure>
    <time_frame>From first day of trial medication intake until end of trial, up to 48 days.</time_frame>
    <description>Percentage of subjects with investigator-defined drug-related Adverse Events (AEs) is reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-24</measure>
    <time_frame>At -0:05 hours (h):minutes (min) before dosing and at 0:15, 0:30, 0:45, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00 and 23:55 h:min after first dose.</time_frame>
    <description>Area under the concentration-time curve of BI 1467335 in plasma over the time interval from 0 to 24 hours after administration of the first dose (AUC0-24).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>At -0:05 hours (h):minutes (min) before dosing and at 0:15, 0:30, 0:45, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00 and 23:55 h:min after first dose.</time_frame>
    <description>Maximum measured concentration of BI 1467335 in plasma after administration of the first dose (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24,28</measure>
    <time_frame>At 647:55 hours (h):minutes (min) prior to dosing and at 648:15, 648:30, 648:45, 649:00, 649:30, 650:00, 651:00, 652:00, 654:00, 656:00, 658:00, 660:00 and 672:00 h:min after first drug administration.</time_frame>
    <description>Area under the concentration-time curve of BI 1467335 in plasma over the time interval from 0 to 24 hours after administration of 28th dose (AUC0-24,28).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,28</measure>
    <time_frame>At 647:55 hours (h):minutes (min) prior to dosing and at 648:15, 648:30, 648:45, 649:00, 649:30, 650:00, 651:00, 652:00, 654:00, 656:00, 658:00, 660:00 and 672:00 h:min after first drug administration.</time_frame>
    <description>Maximum measured concentration of BI 1467335 in plasma following administration of 28th dose (Cmax,28).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 1467335</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1467335</intervention_name>
    <description>Duration - 28 days</description>
    <arm_group_label>BI 1467335</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Duration - 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Healthy male subjects according to the investigator's assessment, based on a complete&#xD;
             medical history including a physical examination, vital signs (Blood Pressure&#xD;
             (BP),Pulse Rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests&#xD;
&#xD;
          -  Japanese ethnicity or Caucasian, according to the following criteria:&#xD;
&#xD;
               -  Japanese; born in Japan, have lived outside of Japan &lt;10 years, and have parents&#xD;
                  and grandparents who were all born in Japan&#xD;
&#xD;
               -  Caucasian&#xD;
&#xD;
          -  Age of 20 to 45 years (incl.)&#xD;
&#xD;
          -  Body Mass Index (BMI) of 18.5 to 25 kg/m2 (incl.) for Japanese and 18.5 to 29.9 kg/m2&#xD;
             (incl.) for Caucasian&#xD;
&#xD;
          -  Signed and dated written informed consent by date of Visit 1 in accordance with Good&#xD;
             Clinical Practice (GCP) and local legislation.&#xD;
&#xD;
          -  Male subjects who agree to minimize the risk of female partners becoming pregnant by&#xD;
             fulfilling any of the following criteria starting from at least 30 days before the&#xD;
             first administration of trial medication and until 30 days after trial completion:&#xD;
&#xD;
               -  Use of adequate contraception, e.g. any of the following methods plus condom:&#xD;
                  combined oral contraceptives, intrauterine device&#xD;
&#xD;
               -  Vasectomised (vasectomy at least 1 year prior to enrolment)&#xD;
&#xD;
               -  Surgically sterilised (including hysterectomy) female partner&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Any finding in the medical examination (including Blood Pressure (BP), Pulse Rate (PR)&#xD;
             or Electrocardiogram (ECG)) is deviating from normal and judged as clinically relevant&#xD;
             by the investigator&#xD;
&#xD;
          -  Any laboratory value outside the reference range that the investigator considers to be&#xD;
             of clinical relevance&#xD;
&#xD;
          -  Any evidence of a concomitant disease judged as clinically relevant by the&#xD;
             investigator&#xD;
&#xD;
          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          -  Surgery of the gastrointestinal tract that could interfere with kinetics of the trial&#xD;
             medication (except appendectomy and simple hernia repair)&#xD;
&#xD;
          -  Diseases of the central nervous system (including but not limited to any kind of&#xD;
             seizures or stroke), and other relevant neurological or psychiatric disorders&#xD;
&#xD;
          -  History of relevant orthostatic hypotension, fainting spells, or blackouts&#xD;
&#xD;
          -  Chronic or relevant acute infections including HIV, viral hepatitis and (or)&#xD;
             tuberculosis or evidence of tuberculosis infection as defined by a positive&#xD;
             QuantiFERON TB-Gold (or TSPOT) test. Subjects with a positive QuantiFERON TB-Gold (or&#xD;
             T-SPOT) test will not participate in the study.&#xD;
&#xD;
          -  History of relevant allergy or hypersensitivity (including allergy to the trial&#xD;
             medication or its excipients)&#xD;
&#xD;
          -  Intake of biologic agents other than current study medication or drugs considered&#xD;
             likely to interfere with the safe conduct of the study&#xD;
&#xD;
          -  Intake of drugs with a long half-life (more than 24 h) within 30 days or less than 10&#xD;
             half-lives of the respective drug prior to administration of trial medication&#xD;
&#xD;
          -  Within 10 days prior to administration of trial medication, use of drugs that might&#xD;
             reasonably influence the results of the trial or that might prolong the QT/QTc&#xD;
             interval&#xD;
&#xD;
          -  Participation in another trial (including bioequivalence trial) with an&#xD;
             investigational drug within 90 days or 5 half-lives (whichever is greater) prior to&#xD;
             planned administration of trial medication&#xD;
&#xD;
          -  Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)&#xD;
&#xD;
          -  Inability to refrain from smoking on specified trial days&#xD;
&#xD;
          -  Alcohol abuse (consumption of more than 30 g per day)&#xD;
&#xD;
          -  Drug abuse or positive drug screening&#xD;
&#xD;
          -  Blood donation of more than 200 mL within 30 days prior to administration of trial&#xD;
             medication or intended donation during the trial&#xD;
&#xD;
          -  Intention to perform excessive physical activities within one week prior to&#xD;
             administration of trial medication or during the trial&#xD;
&#xD;
          -  Inability to comply with dietary regimen of trial site&#xD;
&#xD;
          -  A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are&#xD;
             repeatedly greater than 450 ms) or any other relevant ECG finding at screening&#xD;
&#xD;
          -  A history of additional risk factors for Torsades de Pointes (such as heart failure,&#xD;
             hypokalemia, or family history of Long QT Syndrome)&#xD;
&#xD;
          -  Have received any live bacterial or live viral vaccination in the 12 weeks prior to&#xD;
             the date of screening. Subjects must agree not to receive a live bacterial or live&#xD;
             viral vaccination during the study and up to 12 months after the last administration&#xD;
             of study drug&#xD;
&#xD;
          -  Have received Bacille Calmette-Guerin (BCG) vaccination in the 12 months prior to the&#xD;
             date of screening. Subjects must agree not to receive BCG vaccination during the study&#xD;
             and up to 12 months after the last administration of study drug&#xD;
&#xD;
          -  Subject is assessed as unsuitable for inclusion by the investigator, for instance,&#xD;
             because considered not able to understand and comply with study requirements, or has a&#xD;
             condition that would not allow safe participation in the study&#xD;
&#xD;
          -  Signs of cataract at screening by slit lamp test&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Souseikai Hakata Clinic</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOUSEIKAI Sumida Hospital</name>
      <address>
        <city>Tokyo, Sumida-ku</city>
        <zip>130-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 17, 2017</study_first_submitted>
  <study_first_submitted_qc>May 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <results_first_submitted>May 11, 2021</results_first_submitted>
  <results_first_submitted_qc>May 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 4, 2021</results_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03159455/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT03159455/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This trial was randomised, double-blind, and placebo-controlled within dose groups. There were 3 sequential dose groups and the highest dose group consisted of 2 ethnic subgroups (Japanese and Caucasian ethnicity).</recruitment_details>
      <pre_assignment_details>All subjects were screened for eligibility to participate in trial. Subjects attended specialist sites to ensure that they (the subjects) met all implemented inclusion/exclusion criteria. Subjects were not to be randomised to trial drug if any of the specific entry criteria was violated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo (Japanese)</title>
          <description>Subjects were orally administered matching placebo tablets with 240 milliliter (mL) water after an overnight fast of at least 10 hours (h) in Japanese ethnicity.</description>
        </group>
        <group group_id="P2">
          <title>BI 1467335 3 mg Tablet (Japanese)</title>
          <description>Subjects were orally administered BI 1467335 3 milligram (mg) film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
        </group>
        <group group_id="P3">
          <title>BI 1467335 6 mg Tablet (Japanese)</title>
          <description>Subjects were orally administered BI 1467335 6 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
        </group>
        <group group_id="P4">
          <title>BI 1467335 10 mg Tablet (Japanese)</title>
          <description>Subjects were orally administered BI 1467335 10 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
        </group>
        <group group_id="P5">
          <title>Placebo (Caucasian)</title>
          <description>Subjects were orally administered matching placebo tablets with 240 mL water after an overnight fast of at least 10 h in Caucasian ethnicity.</description>
        </group>
        <group group_id="P6">
          <title>BI 1467335 10 mg Tablet (Caucasian)</title>
          <description>Subjects were orally administered BI 1467335 10 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Caucasian ethnicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set (TS): All subjects who received at least 1 dose of trial medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo (Japanese)</title>
          <description>Subjects were orally administered matching placebo tablets with 240 milliliter (mL) water after an overnight fast of at least 10 hours (h) in Japanese ethnicity.</description>
        </group>
        <group group_id="B2">
          <title>BI 1467335 3 mg Tablet (Japanese)</title>
          <description>Subjects were orally administered BI 1467335 3 milligram (mg) film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
        </group>
        <group group_id="B3">
          <title>BI 1467335 6 mg Tablet (Japanese)</title>
          <description>Subjects were orally administered BI 1467335 6 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
        </group>
        <group group_id="B4">
          <title>BI 1467335 10 mg Tablet (Japanese)</title>
          <description>Subjects were orally administered BI 1467335 10 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
        </group>
        <group group_id="B5">
          <title>Placebo (Caucasian)</title>
          <description>Subjects were orally administered matching placebo tablets with 240 mL water after an overnight fast of at least 10 h in Caucasian ethnicity.</description>
        </group>
        <group group_id="B6">
          <title>BI 1467335 10 mg Tablet (Caucasian)</title>
          <description>Subjects were orally administered BI 1467335 10 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Caucasian ethnicity.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="9"/>
            <count group_id="B7" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.2" spread="5.78"/>
                    <measurement group_id="B2" value="32.8" spread="7.16"/>
                    <measurement group_id="B3" value="25.0" spread="6.58"/>
                    <measurement group_id="B4" value="25.3" spread="2.92"/>
                    <measurement group_id="B5" value="31.3" spread="5.86"/>
                    <measurement group_id="B6" value="33.7" spread="5.92"/>
                    <measurement group_id="B7" value="29.5" spread="6.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Drug-related Adverse Events</title>
        <description>Percentage of subjects with investigator-defined drug-related Adverse Events (AEs) is reported.</description>
        <time_frame>From first day of trial medication intake until end of trial, up to 48 days.</time_frame>
        <population>Treated Set (TS): All subjects who received at least 1 dose of trial medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (Japanese)</title>
            <description>Subjects were orally administered matching placebo tablets with 240 milliliter (mL) water after an overnight fast of at least 10 hours (h) in Japanese ethnicity.</description>
          </group>
          <group group_id="O2">
            <title>BI 1467335 3 mg Tablet (Japanese)</title>
            <description>Subjects were orally administered BI 1467335 3 milligram (mg) film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
          </group>
          <group group_id="O3">
            <title>BI 1467335 6 mg Tablet (Japanese)</title>
            <description>Subjects were orally administered BI 1467335 6 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
          </group>
          <group group_id="O4">
            <title>BI 1467335 10 mg Tablet (Japanese)</title>
            <description>Subjects were orally administered BI 1467335 10 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
          </group>
          <group group_id="O5">
            <title>Placebo (Caucasian)</title>
            <description>Subjects were orally administered matching placebo tablets with 240 mL water after an overnight fast of at least 10 h in Caucasian ethnicity.</description>
          </group>
          <group group_id="O6">
            <title>BI 1467335 10 mg Tablet (Caucasian)</title>
            <description>Subjects were orally administered BI 1467335 10 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Caucasian ethnicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Drug-related Adverse Events</title>
          <description>Percentage of subjects with investigator-defined drug-related Adverse Events (AEs) is reported.</description>
          <population>Treated Set (TS): All subjects who received at least 1 dose of trial medication.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-24</title>
        <description>Area under the concentration-time curve of BI 1467335 in plasma over the time interval from 0 to 24 hours after administration of the first dose (AUC0-24).</description>
        <time_frame>At -0:05 hours (h):minutes (min) before dosing and at 0:15, 0:30, 0:45, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00 and 23:55 h:min after first dose.</time_frame>
        <population>Pharmacokinetic Set (PKS): This subject set included all subjects of the TS who provide at least 1 pharmacokinetic (PK) parameter that was not excluded due to relevant protocol violations or due to PK non-evaluability.</population>
        <group_list>
          <group group_id="O1">
            <title>BI 1467335 3 mg Tablet (Japanese)</title>
            <description>Subjects were orally administered BI 1467335 3 milligram (mg) film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
          </group>
          <group group_id="O2">
            <title>BI 1467335 6 mg Tablet (Japanese)</title>
            <description>Subjects were orally administered BI 1467335 6 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
          </group>
          <group group_id="O3">
            <title>BI 1467335 10 mg Tablet (Japanese)</title>
            <description>Subjects were orally administered BI 1467335 10 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
          </group>
          <group group_id="O4">
            <title>BI 1467335 10 mg Tablet (Caucasian)</title>
            <description>Subjects were orally administered BI 1467335 10 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Caucasian ethnicity.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-24</title>
          <description>Area under the concentration-time curve of BI 1467335 in plasma over the time interval from 0 to 24 hours after administration of the first dose (AUC0-24).</description>
          <population>Pharmacokinetic Set (PKS): This subject set included all subjects of the TS who provide at least 1 pharmacokinetic (PK) parameter that was not excluded due to relevant protocol violations or due to PK non-evaluability.</population>
          <units>nanomole*hour/Liter (nmol*h/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.898" spread="69.4"/>
                    <measurement group_id="O2" value="2.05" spread="31.4"/>
                    <measurement group_id="O3" value="14.7" spread="66.9"/>
                    <measurement group_id="O4" value="6.39" spread="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This was non confirmatory testing (Single dose). Dose proportionality of tablets for AUC0-24 was analysed in Japanese subjects.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>2.2305</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2592</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.6955</ci_lower_limit>
            <ci_upper_limit>2.7655</ci_upper_limit>
            <estimate_desc>Dose proportionality was explored using the power model.The perfect dose proportionality would correspond to a slope β of 1. PK endpoints on the log-transformed scale.</estimate_desc>
            <other_analysis_desc>Standard error of mean is standard error of slope.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax</title>
        <description>Maximum measured concentration of BI 1467335 in plasma after administration of the first dose (Cmax).</description>
        <time_frame>At -0:05 hours (h):minutes (min) before dosing and at 0:15, 0:30, 0:45, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00 and 23:55 h:min after first dose.</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>BI 1467335 3 mg Tablet (Japanese)</title>
            <description>Subjects were orally administered BI 1467335 3 milligram (mg) film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
          </group>
          <group group_id="O2">
            <title>BI 1467335 6 mg Tablet (Japanese)</title>
            <description>Subjects were orally administered BI 1467335 6 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
          </group>
          <group group_id="O3">
            <title>BI 1467335 10 mg Tablet (Japanese)</title>
            <description>Subjects were orally administered BI 1467335 10 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
          </group>
          <group group_id="O4">
            <title>BI 1467335 10 mg Tablet (Caucasian)</title>
            <description>Subjects were orally administered BI 1467335 10 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Caucasian ethnicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum measured concentration of BI 1467335 in plasma after administration of the first dose (Cmax).</description>
          <population>PKS</population>
          <units>nanomole/Liter (nmol/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.791" spread="60.3"/>
                    <measurement group_id="O2" value="1.71" spread="53.9"/>
                    <measurement group_id="O3" value="8.27" spread="64.5"/>
                    <measurement group_id="O4" value="3.42" spread="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This was non confirmatory testing (Single dose). Dose proportionality of tablets for Cmax was analysed in Japanese subjects.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>1.9007</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2382</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4102</ci_lower_limit>
            <ci_upper_limit>2.3912</ci_upper_limit>
            <estimate_desc>Dose proportionality was explored using the power model.The perfect dose proportionality would correspond to a slope β of 1. PK endpoints on the log-transformed scale.</estimate_desc>
            <other_analysis_desc>Standard error of mean is standard error of slope.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-24,28</title>
        <description>Area under the concentration-time curve of BI 1467335 in plasma over the time interval from 0 to 24 hours after administration of 28th dose (AUC0-24,28).</description>
        <time_frame>At 647:55 hours (h):minutes (min) prior to dosing and at 648:15, 648:30, 648:45, 649:00, 649:30, 650:00, 651:00, 652:00, 654:00, 656:00, 658:00, 660:00 and 672:00 h:min after first drug administration.</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>BI 1467335 3 mg Tablet (Japanese)</title>
            <description>Subjects were orally administered BI 1467335 3 milligram (mg) film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
          </group>
          <group group_id="O2">
            <title>BI 1467335 6 mg Tablet (Japanese)</title>
            <description>Subjects were orally administered BI 1467335 6 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
          </group>
          <group group_id="O3">
            <title>BI 1467335 10 mg Tablet (Japanese)</title>
            <description>Subjects were orally administered BI 1467335 10 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
          </group>
          <group group_id="O4">
            <title>BI 1467335 10 mg Tablet (Caucasian)</title>
            <description>Subjects were orally administered BI 1467335 10 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Caucasian ethnicity.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-24,28</title>
          <description>Area under the concentration-time curve of BI 1467335 in plasma over the time interval from 0 to 24 hours after administration of 28th dose (AUC0-24,28).</description>
          <population>PKS</population>
          <units>nanomole*hour/Liter (nmol*h/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" spread="51.1"/>
                    <measurement group_id="O2" value="117" spread="33.7"/>
                    <measurement group_id="O3" value="1120" spread="24.1"/>
                    <measurement group_id="O4" value="721" spread="86.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This was non confirmatory testing on Day 28 (after multiple doses). Dose proportionality of tablets for AUC0-24,28 was analysed in Japanese subjects.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>3.2440</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1771</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.8793</ci_lower_limit>
            <ci_upper_limit>3.6087</ci_upper_limit>
            <estimate_desc>Dose proportionality was explored using the power model.The perfect dose proportionality would correspond to a slope β of 1. PK endpoints on the log-transformed scale.</estimate_desc>
            <other_analysis_desc>Standard error of mean is standard error of slope.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax,28</title>
        <description>Maximum measured concentration of BI 1467335 in plasma following administration of 28th dose (Cmax,28).</description>
        <time_frame>At 647:55 hours (h):minutes (min) prior to dosing and at 648:15, 648:30, 648:45, 649:00, 649:30, 650:00, 651:00, 652:00, 654:00, 656:00, 658:00, 660:00 and 672:00 h:min after first drug administration.</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>BI 1467335 3 mg Tablet (Japanese)</title>
            <description>Subjects were orally administered BI 1467335 3 milligram (mg) film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
          </group>
          <group group_id="O2">
            <title>BI 1467335 6 mg Tablet (Japanese)</title>
            <description>Subjects were orally administered BI 1467335 6 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
          </group>
          <group group_id="O3">
            <title>BI 1467335 10 mg Tablet (Japanese)</title>
            <description>Subjects were orally administered BI 1467335 10 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
          </group>
          <group group_id="O4">
            <title>BI 1467335 10 mg Tablet (Caucasian)</title>
            <description>Subjects were orally administered BI 1467335 10 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Caucasian ethnicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax,28</title>
          <description>Maximum measured concentration of BI 1467335 in plasma following administration of 28th dose (Cmax,28).</description>
          <population>PKS</population>
          <units>nanomole/Liter (nmol/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" spread="58.4"/>
                    <measurement group_id="O2" value="57.2" spread="35.1"/>
                    <measurement group_id="O3" value="159" spread="19.9"/>
                    <measurement group_id="O4" value="124" spread="41.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This was non confirmatory testing on Day 28 (after multiple doses). Dose proportionality of tablets for Cmax,28 was analysed in Japanese subjects.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>2.0711</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1480</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.7663</ci_lower_limit>
            <ci_upper_limit>2.3760</ci_upper_limit>
            <estimate_desc>Dose proportionality was explored using the power model.The perfect dose proportionality would correspond to a slope β of 1. PK endpoints on the log-transformed scale.</estimate_desc>
            <other_analysis_desc>Standard error of mean is standard error of slope.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first day of trial medication intake until end of trial, up to 48 days.</time_frame>
      <desc>Treated Set (TS): All subjects who received at least 1 dose of trial medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Japanese)</title>
          <description>Subjects were orally administered matching placebo tablets with 240 milliliter (mL) water after an overnight fast of at least 10 hours (h) in Japanese ethnicity.</description>
        </group>
        <group group_id="E2">
          <title>BI 1467335 3 mg Tablet (Japanese)</title>
          <description>Subjects were orally administered BI 1467335 3 milligram (mg) film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
        </group>
        <group group_id="E3">
          <title>BI 1467335 6 mg Tablet (Japanese)</title>
          <description>Subjects were orally administered BI 1467335 6 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
        </group>
        <group group_id="E4">
          <title>BI 1467335 10 mg Tablet (Japanese)</title>
          <description>Subjects were orally administered BI 1467335 10 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Japanese ethnicity.</description>
        </group>
        <group group_id="E5">
          <title>Placebo (Caucasian)</title>
          <description>Subjects were orally administered matching placebo tablets with 240 mL water after an overnight fast of at least 10 h in Caucasian ethnicity.</description>
        </group>
        <group group_id="E6">
          <title>BI 1467335 10 mg Tablet (Caucasian)</title>
          <description>Subjects were orally administered BI 1467335 10 mg film-coated tablets once daily with 240 mL water after an overnight fast of at least 10 h for 28 days in Caucasian ethnicity.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Faeces soft</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Eosinophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

